Biomarker Disease Diagnosis Targeted by Thermo Fisher Scientific and Immunodiagnostik Collaboration

Oct 26, 2012
By LCGC Editors

Thermo Fisher Scientific (California, USA) has collaborated with Immunodiagnostik (Bensheim, Germany) to develop novel assays for the commercial qualitative and quantitative analysis of protein and peptide biomarkers in disease diagnosis.

The collaboration seeks to further biomarker research, by combining the antibody-based detection technology developed by Immunodiagnostik with the liquid–chromatrography tandem mass spectrometry (LC–MS–MS) analytical technology from Thermo Scientific. The companies hope to enable the development of assays specifically for the diagnosis of cardiovascular disease and bone metabolism disorders. Furthermore, Immunodiagnostik will utilize its academic and clinical network connections to allow the validation of developed assays.

“We are impressed with Immundiagnostik’s antibody expertise, and are confident that the immunoaffinity-purification of proteins will take quantitative LC–MS–MS protein analysis to the next level,” said Jeff Zonderman, Thermo Fisher director of clinical and toxicology LC–MS.

For more information please visit:

lorem ipsum